The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc. (NASDAQ:TVTX) ranks 7th on this list.

Investor interest in Travere Therapeutics, Inc. (NASDAQ:TVTX) has spiked since a landmark regulatory win. Earlier this month, drug authorities granted full approval of FILSPARI for focal segmental glomerulosclerosis (FSGS). ILSPARI is now the first and only FDA-approved medication for FSGS, a rare disease that often leads to kidney failure. This first-mover advantage is viewed as a massive moat. The approval is broad, covering both adult and pediatric patients. This significantly expanded the drug’s addressable market beyond its existing use in IgA nephropathy. Analysts estimate that the combined US market for IgAN and FSGS exceeds 100,000 patients, with peak domestic sales potential now projected above $3 billion.

Hedge funds like the fact that Travere Therapeutics, Inc. (NASDAQ:TVTX) already has a specialized nephrology sales force of 100+ professionals in the field. This allows for an immediate, high-margin commercial launch without the growing pains of building a new team. Beyond FILSPARI, funds are looking at the next wave of clinical catalysts. Travere is on track to restart its pivotal Phase 3 HARMONY study for pegtibatinase in early 2026. Travere’s partner, Chugai Pharmaceutical, is expected to submit a New Drug Application for sparsentan in Japan this year, which would trigger additional milestone payments and royalties for the company.

While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.